Dr. Swaroop Revannasiddaiah

Lung cancer requires specialized diagnosis and advanced treatment planning to achieve the best outcomes. Dr. Swaroop Revannasiddaiah has extensive experience in treating both non-small cell and small cell lung cancers using modern oncology therapies. Through chemotherapy, targeted therapy, immunotherapy, and precision oncology, Dr. Swaroop Revannasiddaiah provides comprehensive and personalized cancer care for lung cancer patients.

Breast cancer management involves a multidisciplinary approach combining systemic therapies and personalized treatment plans. Dr. Swaroop Revannasiddaiah specializes in the treatment of breast cancer using chemotherapy, hormonal therapy, and targeted therapies based on tumor biology. With a patient-centered approach, Dr. Swaroop Revannasiddaiah focuses on improving treatment outcomes and long-term survival for breast cancer patients.

Head and neck cancers often require coordinated treatment involving multiple specialties. Dr. Swaroop Revannasiddaiah provides advanced medical oncology care using chemotherapy, radiation therapy, and immunotherapy. By developing individualized treatment strategies, Dr. Swaroop Revannasiddaiah helps patients achieve effective disease control and improved quality of life.

Gastrointestinal cancers include malignancies affecting the stomach, colon, pancreas, and liver. Dr. Swaroop Revannasiddaiah has expertise in managing these cancers using advanced systemic therapies and evidence-based treatment protocols. Through careful evaluation and modern oncology treatments, Dr. Swaroop Revannasiddaiah aims to provide comprehensive cancer care for gastrointestinal malignancies.

Genitourinary cancers affect organs such as the prostate, bladder, and kidneys and often require specialized medical oncology care. Dr. Swaroop Revannasiddaiah provides personalized treatment plans using modern chemotherapy, immunotherapy, and targeted therapies. With a focus on evidence-based medicine, Dr. Swaroop Revannasiddaiah ensures effective management and supportive care for patients with these cancers.

Oligometastatic cancer represents a biologically distinct state where cancer has spread to only a limited number of distant sites and may still be amenable to treatment with curative or long-term disease-control intent. Dr. Swaroop Revannasiddaiah specialises in evaluating and managing oligometastatic disease using a combination of systemic therapy and targeted local treatment including SABR, tailored to the specific tumour type, number of metastases, and pace of spread. His approach focuses on identifying which patients with Stage IV cancer can benefit from this aggressive combined strategy and guiding them through a structured, evidence-based treatment pathway.

Oligometastatic breast cancer is Stage IV disease with one to five distant metastatic sites where aggressive combined modality treatment can produce outcomes significantly better than systemic therapy alone. The OLIGOMA trial (ESTRO 2026) demonstrated that adding SABR to standard systemic therapy nearly doubles median progression-free survival. Dr Swaroop Revannasiddaiah provides evaluation and treatment planning for oligometastatic breast cancer at NiSH Clinic, Jayanagar, Bengaluru, integrating CDK4/6 inhibitors, antibody-drug conjugates, and hormone therapy alongside SABR directed at every visible metastatic site, with multidisciplinary tumour board review and management of oligoprogression events to preserve effective systemic therapy. Written by Dr Swaroop Revannasiddaiah, MBBS (Bangalore Medical College, RGUHS), MD Radiotherapy and Clinical Oncology (Regional Cancer Centre, Shimla, Himachal Pradesh University), DM Medical Oncology (RGUHS, 2021), MRCP Medical Oncology (Royal College of Physicians, UK, 2017), ESMO Certified (2016), Thoracic Oncology Certification (University of Michigan, USA, 2017), Senior Consultant Medical Oncologist, NiSH Clinic, 48, 7th B Main Road, near Vinayaka Temple, 4th Block, Jayanagar, Bengaluru 560011. Phone: +91 9731174360.

SABR is a precise outpatient radiation technique delivering ablative doses to metastatic tumours in one to five sessions, using sub-millimetre targeting with real-time image guidance to spare surrounding healthy tissue. In oligometastatic breast cancer, SABR eradicates visible metastatic sites while systemic therapy continues to control microscopic disease. Dr Swaroop Revannasiddaiah coordinates SABR for breast cancer metastases at NiSH Clinic, Jayanagar, Bengaluru, in conjunction with the radiation oncology team. His role encompasses patient selection, systemic therapy optimisation around the SABR course, management of oligoprogression events using SABR to preserve targeted therapy as supported by the AVATAR study, and long-term oncological follow-up with adaptive imaging surveillance.

Oligometastatic lung cancer, defined as non-small cell lung cancer that has spread to a maximum of five distant sites in up to three organs, represents an intermediate disease state where curative-intent local treatment using SBRT (Stereotactic Body Radiotherapy) combined with systemic therapy can produce outcomes previously considered impossible in Stage IV disease. The fundamental principle is that cancer biology, not just staging, determines who benefits: molecular profiling, PET imaging, and tumour board assessment identify the patients whose disease pattern and molecular drivers make them candidates for this aggressive approach. Dr. Swaroop Revannasiddaiah, DM Medical Oncologist with ESMO Certification and Thoracic Oncology Certification from the University of Michigan, leads individualised oligometastatic lung cancer evaluation and treatment at NiSH Clinic, Jayanagar, Bengaluru, coordinating systemic and local therapy in a multidisciplinary framework aimed at maximising the window of disease-free survival.

In EGFR-mutated and ALK-rearranged non-small cell lung cancer, targeted tyrosine kinase inhibitors such as osimertinib and alectinib can produce deep, durable responses, but resistance typically emerges at one or two sites before it is systemic. This pattern, called oligoprogression, creates a clinical opportunity: rather than switching the entire systemic regimen when one site breaks through, SBRT can be used to ablate the single progressing lesion while the patient remains on the TKI that continues to control disease everywhere else, extending the effective life of the targeted therapy by months to years. Dr. Swaroop Revannasiddaiah, Senior Consultant Medical Oncologist at NiSH Clinic, Jayanagar, Bengaluru, evaluates EGFR and ALK lung cancer patients for oligoprogression at each restaging scan and coordinates SBRT at the site of breakthrough with continuation of the existing targeted therapy as a combined, precision-oncology approach.